BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oncobiologics Inc. Appoints Scott Canute, Former President of Eli Lilly and Company (LLY) and Genzyme Corporation (GENZ), to its Board of Directors


10/12/2011 11:53:45 AM

CRANBURY, N.J., Oct. 12, 2011 /PRNewswire/ -- Oncobiologics, Inc. announced today that is has named Scott Canute, a former President at both Eli Lilly and Genzyme, to its Board of Directors.

Over the course of his 30-year career, Mr. Canute played a vital role in leading Eli Lilly's global manufacturing operations. Most recently, he spent more than a year as President of Global Manufacturing and Corporate Operations for Genzyme, where he led a major turnaround effort.

"Scott Canute has been a distinguished leader at major biopharmaceutical organizations throughout his career," said Oncobiologics Founder & CEO Pankaj Mohan, Ph.D. "I have known and admired Scott as my mentor for many years, and I am honored that he will share his experience and strategic insight to our efforts at Oncobiologics. We look forward to guidance from Scott as a member of our board."

"Oncobiologics has assembled an impressive team of industry leaders, and already has developed a promising pipeline," said Mr. Canute. "Although the company is a start-up, it has the horsepower of a much more established organization. I look forward to helping Pankaj steer the company through this exciting stage."

Mr. Canute earned a Master of Business Administration from the Harvard Business School. He also earned a B.S. in Chemical Engineering at the University of Michigan, where he graduated with Highest Honors.

About Oncobiologics, Inc.

Headquartered in Cranbury, N.J., Oncobiologics is utilizing a proprietary platform to develop a pipeline of next generation biotherapeutics focused on clinically validated targets in the therapeutic areas of oncology, immuno-oncology, and immunology. Oncobiologics provides world-class, turnkey proof-of-concept services that can take a partner's pre-clinical candidates from chemistry, manufacture and control development through Phase II clinical trials. For more information, please visit www.oncobiologics.com or call 609-619-3990.

SOURCE Oncobiologics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES